 HOUSTON, Oct. 19, 2022 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. NASDAQ: SLRX, a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiestebans presentation, titled Development of SP-3164, a Cereblon-Binding Molecular Glue, will be delivered at 5:30 p.m. local time on October 26th. 